

Journal Pre-proof

Assay for Hepatitis B Core-related Antigen Identify Patients With High Viral Load: Systematic Review and Meta-analysis of Individual Participant Data

Kyoko Yoshida, Alice Desbiolles, Sarah F. Feldman, Sang Hoon Ahn, Enagnon K. Alidjinou, Masanori Atsukawa, Laurence Bocket, Maurizia R. Brunetto, Maria Buti, Ivana Carey, Gian Paolo Caviglia, En-Qiang Chen, Markus Cornberg, Masaru Enomoto, Masao Honda, Christoph Höner Zu Siederdisen, Masatoshi Ishigami, Harry LA. Janssen, Benjamin Maasoumy, Takeshi Matsui, Akihiro Matsumoto, Shuhei Nishiguchi, Mar Riveiro-Barciela, Akinobu Takaki, Pisit Tangkijvanich, Hidenori Toyoda, Margo JH. van Campenhout, Bo Wang, Lai Wei, Hwai-I. Yang, Yoshihiko Yano, Hiroshi Yatsuhashi, Man-Fung Yuen, Eiji Tanaka, Maud Lemoine, Yasuhito Tanaka, Yusuke Shimakawa



PII: S1542-3565(20)30590-5
DOI: <https://doi.org/10.1016/j.cgh.2020.04.045>
Reference: YJCGH 57163

To appear in: *Clinical Gastroenterology and Hepatology*
Accepted Date: 10 April 2020

Please cite this article as: Yoshida K, Desbiolles A, Feldman SF, Ahn SH, Alidjinou EK, Atsukawa M, Bocket L, Brunetto MR, Buti M, Carey I, Caviglia GP, Chen E-Q, Cornberg M, Enomoto M, Honda M, Zu Siederdisen CH, Ishigami M, Janssen HL, Maasoumy B, Matsui T, Matsumoto A, Nishiguchi S, Riveiro-Barciela M, Takaki A, Tangkijvanich P, Toyoda H, van Campenhout MJ, Wang B, Wei L, Yang H-I, Yano Y, Yatsuhashi H, Yuen M-F, Tanaka E, Lemoine M, Tanaka Y, Shimakawa Y, Assay for Hepatitis B Core-related Antigen Identify Patients With High Viral Load: Systematic Review and Meta-analysis of Individual Participant Data, *Clinical Gastroenterology and Hepatology* (2020), doi: <https://doi.org/10.1016/j.cgh.2020.04.045>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Table 1. Characteristics of 5,591 study participants without antiviral therapy by 23 study centers, and 4,806 study participants under antiviral therapy by 19 study centers

References*	Coordinating Center	Year published	Country	HBV DNA assay	No. of IPD	Median age (INR)	Male sex (%)	HIV (%)	HCV (%)	HDV (%)	HBe Ag (%)	HBV genotype (%)
Participants without antiviral therapy												
1-15	Shinshu University	2001-2018	Japan	TaqMan/Amplicor/Accugen e/DNAprobe/in-house PCR/TMA	808	57 (46-63)	70	0	0	-	24	A:2, B:12, C:85, F:1
16-18	Nagoya City University	2006-2013	Japan	TaqMan/in-house PCR/TMA	521	56 (47-62)	49	-	0	-	7	A:2, B:52, C:46
19	St Marianna University	2010	Japan	Amplicor/DNAprobe	10	32 (24-40)	80	0	0	-	80	C:100
20	Nagasaki Medical Centre	2012	Japan	TaqMan	234	38 (30-47)	69	0	0	-	39	A:1, B:1, C:98
21-23	Ogaki Municipal Hospital	2013-2018	Japan	TaqMan	948	49 (37-59)	56	-	0	-	29	A:4, B:10, C:84, D:1, F:1
24-26	Osaka City University	2013-2018	Japan	TaqMan/Amplicor/TMA	102	35 (30-42)	87	-	0	-	81	A:4, B:1, C:95
27	Teine Keijinkai Hospital	2016	Japan	TaqMan	17	42 (35-55)	53	0	0	-	27	B:24, C:76
28	Kobe University	2017	Japan	TaqMan	27	34 (31-39)	59	-	0	-	67	B:7, C:93
29	Nippon Medical School	2018	Japan	TaqMan	218	58 (47-66)	51	-	0	-	10	A:8, B:20, C:71, D:1

30-33	University of Hong Kong	2007-2017	China	TaqMan	652	45 (35-53)	68	0	0	0	48	B:45, C:55
34,35	Peking University	2016	China	TaqMan	111	25 (22-32)	77	0	0	0	100	B:34, C:66
36,37	Sichuan University	2017-2018	China	TaqMan	63	26 (23-33)	76	0	0	-	100	B:57, C:43
38	Academia Sinica	2018	Taiwan	TaqMan	316	37 (33-44)	64	-	0	-	100	B:47, C:53
39,40	Chulalongkorn University	2016-2017	Thailand	RealTime	167	37 (31-45)	70	0	0	0	28	A:1, B:19, C:79, G:1
41	Mongolian Academy of Sciences	2008	Mongolia	in-house PCR	57	40 (30-54)	52	-	25	42	14	A:4, C:6, D:90
42	University of Turin	2016	Italy	TaqMan	28	57 (52-59)	71	0	0	0	0	D:100
43,44	University of Pisa	2017-2018	Italy	TaqMan	253	46 (34-54)	59	0	4	40	3	A:5, B:1, D:92, E:1, F:1
45	Hannover Medical School	2015	Germany	TaqMan	283	33 (24-46)	58	0	0	0	40	A:23, B:9, C:4, D:64
46	Vall d'Hebron Hospital	2017	Spain	TaqMan	134	51 (38-59)	54	0	0	0	0	A:49, B:1, C:1, D:28, E:12, F:6, H:3
47	King's College	2017	UK	TaqMan	162	39 (32-47)	59	-	-	-	100	A:11, B:17, C:33, D:11, E:26, F:1, G:1
48	CHU de Lille	2018	France	TaqMan	13	28 (20-40)	62	8	-	-	15	A:40, B:20, C:10, D:20, E:10
49	Erasmus University	2016	Netherlands	TaqMan	174	30 (24-38)	71	0	0	0	100	A:7, B:19, C:43, D:31
50	MRC Unit, The Gambia	2019	Gambia	in-house PCR	293	37 (30-46)	65	3	3	5	13	A:15, E:85

References*	Coordinating Center	Year published	Country	HBV DNA assay	No. of IPD	Type of treatment	Median age (INR)	Male sex (%)	HIV (%)	HCV (%)	HDV (%)	HBe Ag (%)	HBV genotype (%)
Participants under antiviral therapy													
3-8,10-13,15	Shinshu University	2003-2018	Japan	TaqMan/Amplicor/Accugene/DNAprobe/in-house PCR/TMA	3304	NA: 3167 IFN: 120	58 (47-65)	74	2	0	-	29	A:1, B:10, C:87, F:2
16,18	Nagoya City University	2006-2013	Japan	TaqMan/in-house PCR/TMA	22	NA: 22	46 (39-52)	59	-	0	-	0	B:10, C:90
51,52	Nagasaki University	2009-2013	Japan	Amplicor	13	NA: 13	55 (48-59)	54	-	13	-	39	-
27,53	Teine Keijinkai Hospital	2009-2016	Japan	TaqMan	44	NA: 44	58 (49-62)	80	0	0	-	7	B:8, C:92
19	St Marianna University	2010	Japan	Amplicor/DNAprobe	12	IFN: 12	-	-	0	0	-	36	C:100
54	Okayama University	2011	Japan	TaqMan/DNAprobe	14	NA: 14	50 (44-52)	93	0	14	-	54	C:100
24-26	Osaka City University	2013-2018	Japan	TaqMan/Amplicor/TMA	128	NA: 65 IFN: 63	35 (31-42)	81	-	0	-	63	A:3, B:2, C:95
55,56	Kanazawa University	2016-2018	Japan	TaqMan	281	NA: 281	60 (50-66)	65	-	0	-	23	B:11, C:88, D:1
28	Kobe University	2017	Japan	TaqMan	13	IFN: 13	32 (28-38)	77	-	0	-	85	B:15, C:85
57	Nagoya University	2018	Japan	TaqMan	38	NA: 38	52 (40-62)	61	11	4	-	50	A:17, B:5, C:78
30,31,33,5	University of	2007-	China	TaqMan	542	NA: 542	53 (43-	76	0	0	0	14	B:31,

8	Hong Kong	2017					61)						C:69
34	Peking University	2016	China	TaqMan	58	INF: 58	28 (23-36)	79	0	0	0	86	B:34, C:66
36,37	Sichuan University	2017-2018	China	TaqMan	32	NA: 32	27 (22-35)	75	0	0	-	100	B:66, C:34
59	Yonsei University	2016	Korea	Amplicor	110	NA: 110	50 (40-56)	62	0	0	0	41	C:100
42	University of Turin	2016	Italy	TaqMan	28	NA: 20 IFN: 8	57 (52-60)	71	0	0	0	0	D:100
44	University of Pisa	2017-2018	Italy	TaqMan	12	NA: 8 IFN: 4	47 (41-54)	58	0	25	100	17	D:100
60	Hannover Medical School	2016	Germany	TaqMan	12	NA: 12	49 (46-55)	67	0	0	0	0	B:17, C:8, D:75
47	King's College	2017	UK	TaqMan	94	NA: 94	42 (35-51)	60	-	-	-	100	A:12, B:12, C:33, D:13, E:28, F:1, G:1
48	CHU de Lille	2018	France	TaqMan	49	NA: 49	46 (40-54)	82	27	-	-	12	A:32, B:5, D:26, E:37

* The references of these studies are listed in the Supplementary Document 3.

Abbreviations: IFN, interferon-based therapy; NA, nucleos(t)ide analogue

Table 2. Characteristics of study participants by the concurrent antiviral therapy (N=10,397)

Variables		Without antiviral therapy (n=5,591)	Under antiviral therapy (n=4,806)
Median age (IQR)		45 (34-57)	56 (45-64)
Male sex (%)		3,482 (62%)	3,514 (73%)
Positive HBeAg (%)		2,032 (37%)	1,468 (31%)
HBV DNA (IU/ml)	Undetectable	692 (12%)	3,080 (64%)
	< 2,000	1,550 (27%)	1,256 (26%)
	2,000–19,999	506 (9%)	155 (3%)
	20,000-199,999	448 (8%)	116 (3%)
	≥ 200,000	2,395 (43%)	199 (4%)
HBcrAg (log U/ml)	Undetectable	1,811 (32%)	1,269 (26%)
	3.0 – 3.9	832 (15%)	1,074 (22%)
	4.0 – 4.9	423 (8%)	1,071 (22%)
	5.0 – 6.9	903 (16%)	1,201 (25%)
	≥ 7.0	1,622 (29%)	191 (4%)
HBV genotype	A	287 (6%)	74 (2%)
	B	1,027 (20%)	429 (11%)
	C	2,861 (57%)	3,392 (84%)
	D	538 (11%)	67 (2%)
	E	270 (5%)	34 (<1%)
	F	21 (1%)	61 (1%)
	G	2 (<1%)	1 (<1%)
	H	3 (<1%)	0 (0%)
Co-infection	HIV	10/2,240 (<1%)	16/991 (2%)
	HCV	49/4,465 (1%)	7/1,411 (<1%)
	HDV	156/2,031 (8%)	12/762 (2%)

HBcrAg: hepatitis B core-related antigen; HBeAg: hepatitis B e antigen; HBV: hepatitis B virus;

HCV: hepatitis C virus; HDV: hepatitis D virus; IQR: interquartile range

Table 3. Performance of serum HBcAg to diagnose clinically important HBV DNA levels in untreated patients*

		HBV DNA $\geq 2,000$ IU/ml					HBV DNA $\geq 20,000$ IU/ml					HBV DNA $\geq 200,000$ IU/ml				
		AUROC	Sen	Spe	CC	p^\dagger	AUROC	Sen	Spe	CC	p^\dagger	AUROC	Sen	Spe	CC	p^\dagger
Derivation set (2,796)		0.89 (0.84-0.94)	84.5	84.5	84.5	N/A	0.95 (0.93-0.97)	89.3	89.6	89.5	N/A	0.96 (0.94-0.98)	91.1	91.1	91.1	N/A
Validation set (2,795)		0.88 (0.83-0.93)	85.2	84.7	85.0	N/A	0.95 (0.93-0.97)	90.4	91.9	91.1	N/A	0.96 (0.94-0.99)	91.8	90.5	91.1	N/A
Women of reproductive age (1,134)		0.91 (0.85-0.96)	87.3	78.5	84.4	N/A	0.96 (0.93-0.99)	92.2	87.1	90.0	N/A	0.98 (0.96-1.00)	94.1	89.5	91.8	N/A
Sex	Males (3,482)	0.89 (0.84-0.94)	84.9	82.7	84.1	0.6	0.94 (0.92-0.97)	88.5	89.1	88.8	0.3	0.96 (0.93-0.98)	90.1	89.0	89.5	0.1
	Females (2,098)	0.87 (0.81-0.93)	83.5	87.0	85.1		0.96 (0.94-0.98)	91.9	91.8	91.8		0.98 (0.96-0.99)	93.1	93.3	93.2	
Age group	<30 years (892)	0.92 (0.87-0.98)	91.6	64.4	85.9	0.2	0.97 (0.94-1.00)	95.0	81.6	91.1	0.2	0.98 (0.95-1.00)	96.3	83.7	91.9	0.3
	≥ 30 years (4,679)	0.87 (0.81-0.93)	83.1	86.4	84.5		0.95 (0.92-0.97)	89.2	91.2	90.2		0.96 (0.94-0.98)	90.1	91.5	90.9	
Region	Asia (4,251)	0.89 (0.83-0.94)	84.8	87.2	85.7	0.9	0.94 (0.92-0.97)	89.0	90.1	89.5	0.5	0.96 (0.93-0.98)	89.6	90.0	89.8	0.5
	Europe (1,047)	0.86 (0.69-1.00)	83.4	74.7	80.0		0.98 (0.93-1.00)	95.4	91.4	93.4		0.99 (0.95-1.00)	96.9	93.3	94.9	
	Africa (293)	0.85 (0.77-0.93)	80.2	83.9	83.0		0.92 (0.85-0.99)	89.8	89.8	89.8		0.94 (0.88-1.00)	92.8	92.5	92.5	
HBeAg	Positive (2,032)	0.91 (0.87-0.96)	97.9	23.4	95.0	<0.01	0.87 (0.82-0.93)	98.8	21.0	93.3	0.7	0.86 (0.81-0.91)	98.1	25.6	88.7	0.08
	Negative (3,407)	0.74 (0.63-0.85)	66.0	87.2	79.4		0.89 (0.84-0.95)	77.2	94.5	90.3		0.93 (0.88-0.98)	79.5	97.0	94.4	
HBV genotype	A (287)	0.83 (0.71-0.94)	75.8	89.8	82.5	0.7	0.93 (0.84-1.00)	85.6	93.3	90.4	0.9	0.95 (0.87-1.00)	90.5	92.9	92.2	0.9
	B (1,027)	0.87 (0.79-0.96)	85.0	93.6	88.5		0.95 (0.91-0.99)	91.6	94.8	93.2		0.97 (0.94-1.00)	92.3	93.0	92.7	
	C (2,861)	0.90 (0.85-0.96)	86.8	84.6	86.0		0.95 (0.92-0.99)	91.0	88.4	89.9		0.96 (0.94-0.99)	91.2	88.6	89.9	

	D (538)	0.80 (0.55-1.00)	78.2	63.6	70.8		0.96 (0.89-1.00)	91.4	89.4	90.1		0.98 (0.92-1.00)	93.2	94.0	93.7	
	E (270)	0.88 (0.60-1.00)	85.4	85.9	85.7		0.95 (0.91-0.99)	94.6	87.8	89.8		0.96 (0.89-1.00)	95.1	90.5	91.8	
HCV	Positive (49)	0.92 (0.82-1.00)	89.8	78.3	81.6	0.5	0.97 (0.92-1.00)	94.8	82.9	85.1	0.5	0.98 (0.94-1.00)	95.6	84.5	85.6	0.2
	Negative (4,416)	0.89 (0.83-0.94)	84.9	85.4	85.1		0.95 (0.93-0.98)	90.3	90.6	90.4		0.96 (0.94-0.98)	91.3	90.9	91.1	
HDV	Positive (156)	0.88 (0.81-0.96)	85.3	83.4	83.7	0.9	0.96 (0.93-0.99)	92.0	89.3	89.5	0.9	0.97 (0.94-0.99)	93.3	90.3	90.4	0.9
	Negative (1,875)	0.89 (0.84-0.94)	85.2	88.4	86.1		0.95 (0.93-0.98)	90.8	91.2	91.0		0.97 (0.95-0.99)	91.7	91.0	91.4	

* Optimal cut-offs for serum HBcrAg derived from the derivation set were 3.6 log U/ml to diagnose HBV DNA $\geq 2,000$ IU/ml, 4.5 log U/ml for $\geq 20,000$ IU/ml, and 5.3 log U/ml for $\geq 200,000$ IU/ml.

† p for interaction for AUROC

AUROC: area under the receiver operating characteristic curve; CC, correctly classified; CI: confidence interval; HBcrAg: hepatitis B core-related antigen;

HBeAg: hepatitis B e antigen; HBV: hepatitis B virus; HCV: hepatitis C virus; HDV: hepatitis D virus; Sen, sensitivity; Spe, specificity




Figure 1. Flow diagram of study selection




Figure 2. Correlation between HBcrAg & HBV DNA levels with locally weighted scatter plot smoothing (LOWESS) in patients without treatment, by viral genotypes

Journal Pre-proof




Figure 3. Receiver operating characteristic curves for HBsAg to diagnose clinically important HBV DNA levels (dash: 22,000 IU/mL; short dash: 220,000; solid: 2200,000)

Journal Pre-proof

Title

Hepatitis B core-related antigen to indicate high viral load: systematic review & meta-analysis of 10,397 individual participants

Authors

Kyoko Yoshida^{1*}, Alice Desbiolles^{2*}, Sarah F Feldman^{2*}, Sang Hoon Ahn³, Enagnon K Alidjinou⁴, Masanori Atsukawa⁵, Laurence Bocket⁴, Maurizia R Brunetto⁶, Maria Buti⁷, Ivana Carey⁸, Gian Paolo Caviglia⁹, En-Qiang Chen¹⁰, Markus Cornberg¹¹, Masaru Enomoto¹², Masao Honda¹³, Christoph Höner Zu Siederdissen¹¹, Masatoshi Ishigami¹⁴, Harry LA Janssen¹⁵, Benjamin Maasoumy¹¹, Takeshi Matsui¹⁶, Akihiro Matsumoto¹⁷, Shuhei Nishiguchi¹⁸, Mar Riveiro-Barciela⁷, Akinobu Takaki¹⁹, Pisit Tangkijvanich²⁰, Hidenori Toyoda²¹, Margo JH van Campenhout²², Bo Wang⁸, Lai Wei²³, Hwai-I Yang²⁴, Yoshihiko Yano²⁵, Hiroshi Yatsunami²⁶, Man-Fung Yuen²⁷, Eiji Tanaka²⁸, Maud Lemoine¹, Yasuhito Tanaka²⁹, Yusuke Shimakawa²

* These authors contributed equally.

Affiliations

¹ Department of Surgery and Cancer, Liver Unit, Imperial College London, Praed St, Paddington, London W2 1NY, UK

² Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, 25-28 Rue du Dr Roux, 75015 Paris, France

³ Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea

⁴ Laboratoire de Virologie, Centre de Biologie Pathologie, CHU de Lille, Boulevard du Professeur Jules Leclercq, 59037 Lille, France.

⁵ Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamakari, Inzai, Chiba 270-1694, Japan

⁶ Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, University Hospital of Pisa, Lungarno Antonio Pacinotti, 43, 56126 Pisa PI, Italy

⁷ Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron and Universitat Autònoma de Barcelona, Passeig Vall Hebron, 119-129, 08035, Barcelona, Spain

⁸ Institute of Liver Studies, King's College Hospital, Denmark Hill, Brixton, London SE5 9RS, UK

⁹ Department of Medical Sciences, University of Turin, Corso Dogliotti 14, Turin 10126, Italy

¹⁰ Center of Infectious Diseases, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Wuhou District, Chengdu 610041, China

¹¹ Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg Strasse 1, 30625 Hannover, Germany

¹² Department of Hepatology, Graduate School of Medicine, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan

¹³ Department of Gastroenterology, and Department of Advanced Medical Technology, Kanazawa University Graduate School of Health Medicine, 13-1 Takara-Machi, Kanazawa, Ishikawa 920-8641, Japan

¹⁴ Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan

¹⁵ Toronto Centre for Liver Disease, Toronto General Hospital, University Of Toronto, 200 Elizabeth Street, Eaton Building 9th floor Room 234 (9EB234), Toronto, ON, Canada

¹⁶ Center for Gastroenterology, Teine-Keijinkai Hospital, 12-1-40 Maeda-ichijo, Teine, Sapporo, Hokkaido 006-0811, Japan

¹⁷ Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan

¹⁸ Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawacho, Nishinomiya, Hyogo 663-8501, Japan

¹⁹ Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

²⁰ Center of Excellence in Hepatitis and Liver cancer, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd, 10330, Bangkok, Thailand

²¹ Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, Gifu 503-8502, Japan

²² Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

²³ Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing 100044, China

²⁴ Genomics Research Center, Academia Sinica, 128 Academia Road, Nankang, Taipei 11529, Taiwan

²⁵ Center for Infectious Diseases, Department of Gastroenterology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

²⁶ Clinical Research Center, National Hospital Organization (NHO), Nagasaki Medical Center, 2-1001-1, Kubara, Omura, Nagasaki 856-8562, Japan

²⁷ Department of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China

²⁸ Department for the Promotion of Regional Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan

²⁹ Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho, Nagoya 467-8601, Japan

Corresponding author

Yusuke Shimakawa

Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, 25-28 rue du Dr Roux, 75015 Paris, France

Phone: +33 (0) 1 40 61 38 87

Fax: +33 (0) 1 45 68 88 76

Email: yusuke.shimakawa@pasteur.fr

Conflict of Interest Statement

Brunetto MR received grants and personal fees from AbbVie and Gilead, grants from BMS, and research support from Fujirebio. MB received grants and personal fees from Gilead. GPC received grants from Fujirebio Europe. MC received personal fees from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Roche, Merck, MSD, Biogen, Falk Foundation, Boehringer Ingelheim, Siemens, and Spring Bank, grants from Roche. CHS received grants from Novartis Pharma and Gilead Sciences. HLAJ received grants and personal fees from AbbVie, Bristol Myers Squibb, Gilead Sciences, Janssen, MedImmune, Merck, and Roche, personal fees from Benitec, Arbutus, and Vir Biotechnology Inc. BM received grants from Fujirebio, Roche Diagnostics, Abbott Diagnostics, Fujirebio Europe, and Altona Diagnostics, personal fees from Abbott Diagnostics, Merck/MSD, AbbVie, Falk foundation, and Astellas, and research support Merck/MSD, Gilead, AbbVie. HT received personal fees from AbbVie and MSD. MJHC received personal fees from Fujirebio Europe. YT received grants and personal fees from Fujirebio. All other authors declared no competing interests.

Author Contributions

KY contributed through the acquisition of data, statistical analysis, and drafting of the manuscript.

AD contributed through the acquisition of data, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content.

SFF contributed through the acquisition of data, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content.

SHA contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

EKA contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

MA contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

LB contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

MR Brunetto contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

MB contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

IC contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

GPC contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

EQC contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

MC contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

ME contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

MH contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

CHZS contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

MI contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

HLAJ contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

BM contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

TM contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

AM contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

SN contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

M Riveiro-Barciela contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

AT contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

PT contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

HT contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

MJHC contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

BW contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

LW contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

HIY contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

YY contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

HY contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

MFY contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

ET contributed through the acquisition of data, and critical revision of the manuscript for important intellectual content.

ML contributed through the acquisition of data, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content.

YT contributed through the acquisition of data, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content

YS contributed through the development of study concept and design, acquisition of data, statistical analysis, analysis and interpretation of data, and drafting of the manuscript.

Journal Pre-proof

List of Abbreviations

AUROC	Area under the receiver operating characteristic curve
cccDNA	Covalently closed circular DNA
CHB	Chronic HBV infection
HBcAg	Hepatitis B core antigen
HBcrAg	Hepatitis B core-related antigen
HBeAg	Hepatitis B e antigen
HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HDV	Hepatitis D virus
HCVcAg	HCV core antigen
IFN	Interferon
IPD	Individual participant data
IQR	Interquartile range
LMICs	Low- and middle-income countries
LOWESS	Locally weighted scatter plot smoothing
NA	Nucle(t)ide analogue
NAT	Nucleic acid testing
PRISMA-IPD	Preferred Reporting Items for a Systematic Review and Meta-Analysis of Individual Participant Data
QUADAS-2	Quality Assessment of Diagnostic Accuracy Studies
ROC	Receiver operating characteristic
RT-PCR	Real-time polymerase chain reaction
TMA	Transcription mediated amplification
WHO	World Health Organization
95% CI	95% confidence interval

Abstract (<260 words)

Background and Aims

To eliminate HBV infection, scale-up of testing and treatment in resource-limited countries is crucial. However, access to nucleic acid testing (NAT) to quantify HBV DNA, an essential test to examine treatment eligibility, remains severely limited. We assessed the performance of novel immunoassay, HBV core-related antigen (HBcrAg), as a low-cost (US\$<15/assay) alternative to NAT to indicate clinically important high viremia in chronic HBV patients infected with different genotypes.

Methods

We searched Medline/Embase/Scopus/Web of Science until 06/27/2018. Three reviewers independently selected studies measuring HBV DNA and HBcrAg in the same blood samples. We contacted authors to provide individual participant data (IPD). We randomly allocated each IPD to derivation or validation cohort. We applied optimal HBcrAg cut-offs derived from the derivation set to the validation set to estimate sensitivity/specificity.

Results

Of 74 eligible studies, IPD were successfully obtained for 60 (81%). Meta-analysis included 5,591 IPD without antiviral therapy and 4,806 under antivirals. In untreated patients, pooled area under the receiver operating characteristic curve and optimal cut-offs (log U/ml) were: 0.88 (95%CI: 0.83-0.94) and 3.6 to diagnose HBV DNA level $\geq 2,000$ IU/ml; and 0.96 (0.94-0.98) and 5.3 for $\geq 200,000$ IU/ml, respectively. In the validation set, the sensitivity and specificity were 85.2% and 84.7% for $\geq 2,000$ IU/ml, and 91.8% and 90.5% for $\geq 200,000$ IU/ml, respectively. The performance did not vary by HBV genotypes. In patients under anti-HBV therapy the correlation between HBcrAg and HBV DNA was poor.

Conclusion

HBcrAg might be useful serological marker to indicate clinically important high viremia in treatment-naïve HBV-infected patients.

Keywords

Hepatitis B core-related antigen; diagnosis; sensitivity and specificity; systematic review and meta-analysis

Journal Pre-proof

Introduction

Viral hepatitis, the 7th leading cause of death worldwide, kills more people than any of the major infectious diseases (HIV/tuberculosis/malaria), and is now targeted by the United Nations Sustainable Development Goals.¹ Hepatitis B virus (HBV) infection accounts for more than half of these hepatitis-related deaths. In 2016, the World Health Organization (WHO) developed a global strategy to eliminate hepatitis B as a public health threat, and one of the goals is to increase antiviral treatment uptake from 8% in 2015 to 80% by 2030 in people with chronic HBV infection (CHB) who are eligible for antiviral therapy.¹ To achieve this objective, it is urgent to scale up both hepatitis B surface antigen (HBsAg) screening and clinical staging for people carrying HBsAg to assess their eligibility for anti-HBV therapy.

Following a positive HBsAg screening test, it is essential to quantify serum HBV DNA levels using nucleic acid test (NAT) to decide whether antiviral treatment should be initiated. According to the international guidelines, having high viremia ($\geq 2,000$ or $\geq 20,000$ IU/ml) in the presence of liver inflammation or fibrosis indicates treatment eligibility.²⁻⁵ Recently, the cut-off of $\geq 200,000$ IU/ml has been applied to select pregnant women who would benefit most from antiviral prophylaxis to prevent mother-to-child transmission.^{3,4} However, real-time polymerase chain reaction (RT-PCR), a standard NAT assay to quantify HBV DNA levels, is not affordable and accessible in many low- and middle-income countries (LMICs) because of its high cost (US\$ 60-200/assay) and strict laboratory requirements for sophisticated equipment and well-trained staff.¹ Since the vast majority (>95%) of people with CHB live in LMICs,⁶ the limited access to RT-PCR represents a major obstacle to achieve global hepatitis elimination, and WHO fully recognizes an urgent need for a low-cost simple assay to measure active HBV replication.²

Likewise, the limited access to NAT to diagnose chronic hepatitis C virus (HCV) infection remains an important barrier to expand anti-HCV treatment in LMICs. A systematic review was therefore undertaken to evaluate the accuracy of an immunoassay (HCV core antigen (HCVcAg)) as a low-cost alternative to NAT, and found a comparable clinical sensitivity to the reference NAT assay.⁷ Based on

these data WHO now recommends the use of HCVcAg for the detection of HCV RNA when NAT is not accessible.²

HBV core-related antigen (HBcrAg) is a novel immunoassay to measure HBV replication. The assay quantifies HBV core antigen (HBcAg), e antigen (HBeAg) as well as p22cr and c-terminal modified HBcAg contained in the empty particle fraction in blood regardless of anti-HBc or anti-HBe antibodies.^{8,9} A close correlation between serum HBcrAg levels and HBV DNA levels has been suggested in treatment-naïve patients with CHB.¹⁰⁻¹⁴ Moreover, a correlation of serum HBcrAg levels with intrahepatic covalently closed circular DNA (cccDNA), a transcriptional template of HBV, has been also observed in several Asian and European studies.^{10,11,15,16} Because this immunoassay is cheaper (US\$ <15/assay) and simpler than the RT-PCR, HBcrAg may potentially represent an attractive alternative to HBV DNA PCR in resource-limited countries, and also for hard-to-reach populations living in high-income countries. However, its capability to discriminate between high and low serum HBV DNA levels across different HBV genotypes has never been formally assessed.

We conducted a systematic review and meta-analysis to estimate the sensitivity and specificity of HBcrAg test to diagnose three clinically important HBV DNA thresholds ($\geq 2,000$, $\geq 20,000$, and $\geq 200,000$ IU/ml) determined by the reference NAT assays in patients with CHB. We also conducted subgroup analyses according to viral genotypes. To synthesize these estimates, we sought individual participant data (IPD) from each eligible study, because aggregate data at these specific HBV DNA cut-offs were rarely reported in the previous literatures with few exceptions.¹⁴

Materials and Methods

Our systematic review followed a protocol registered at PROSPERO (CRD42017055440), and was reported according to the Preferred Reporting Items for a Systematic Review and Meta-Analysis of Individual Participant Data (The PRISMA-IPD) guidelines.¹⁷ This meta-analysis was exempt from ethical approval because the analysis only used anonymized data, and all the original studies had received ethics approval.

Data Sources and Searches

Ovid Medline, Ovid Embase, Scopus, and Web of Science were searched from 1st January, 2000 to 27th June, 2018. Following search terms and their variations were used: hepatitis B, core, antigen, and HBcrAg (see Supplementary Document 1 for detailed search strategy). A manual search through bibliographies was also conducted. Three authors (KY, AD, and SFF) independently screened the titles and abstracts of identified citations using pre-specified eligibility criteria. Full-text reading was performed for the potentially eligible citations to examine their eligibility. Disagreements were resolved by another reviewer (YS).

Study Selection

Studies that measured both HBV DNA and HBcrAg levels using the same blood sample from the same individuals with CHB were eligible for the analysis. These individuals needed to be stratified by the presence of concurrent antiviral treatment. Single case reports, letters, reviews, conference abstracts, and those included only patients with hepatocellular carcinoma (HCC) were excluded. Study inclusion was not restricted by language, sample size or participants' age.

Data Extraction and Quality Assessment

Two authors (KY and SFF) independently extracted the following information using a pre-piloted standardized form: study design, settings, objectives, number of participants, participants' selection methods and criteria, participants' characteristics, type and condition of samples used to measure HBcrAg and HBV DNA, and assay methods. Citations in foreign language were translated and the data was extracted by native speakers using the same data extraction sheet. Unless all the necessary individual-level data were reported in the original article, corresponding authors of the eligible papers were systematically invited to be a co-investigator of the current work by e-mail, and asked to provide the IPD using a standardized spreadsheet for the following variables: age, sex, HBcrAg levels, HBV DNA levels, NAT type, HCC status, concurrent anti-HBV treatment, types and conditions of samples, HBeAg sero-status, HBV genotype, and HCV/HIV/HDV co-infection. In case of no response after

four weeks, a reminder was sent. Studies without IPD were excluded from our analysis. The IPD were systematically examined for their integrity, including consistency and completeness. The risk of bias and quality assessment were performed using a tool adapted from the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2),¹⁸ which is available in the Supplementary Document 2.

Data Synthesis and Analysis

Because some study centers generated multiple eligible studies, and these studies often used the data from the same individuals more than once, general characteristics of the IPD were presented by study center, rather than by each study, to avoid double counting. For the quantitative analysis, the quantification limit of the HBcrAg assay minus 0.1 (i.e., 2.9 log U/ml) was assigned to samples with undetectable HBcrAg. Virological characteristics were compared between those with and without antiviral therapy using Wald test with robust standard error to account for clustering within the centers. The linear correlation between HBcrAg levels and HBV DNA levels was evaluated quantitatively using Pearson's correlation coefficient, and visually using a locally weighted scatter plot smoothing (LOWESS). One step approach was used for the meta-analysis in which the IPD from all studies were modelled simultaneously while taking account for clustering of patients within the study centers.¹⁹ The capabilities of HBcrAg to correctly discriminate serum HBV DNA levels at the cut-off of $\geq 2,000$, $\geq 20,000$, and $\geq 200,000$ IU/ml were evaluated by using the receiver operating characteristic (ROC) curve. Our primary outcome measure was pooled area under the ROC curve (AUROC), which was obtained by the parametric two-stage model developed by Alonzo and Pepe²⁰ to account for the clustering within the centers. To estimate the 95% confidence interval (95% CI) of the AUROC, 1,000 bootstrap replications were used. Each non-treated individual was randomly allocated to derivation or validation cohort (1:1). Using the derivation set, the optimal HBcrAg cut-offs were determined to minimize the absolute difference between sensitivity and specificity. These cut-offs were then applied to the validation set to obtain the pooled sensitivity and specificity. The proportion correctly classified was computed as below: disease prevalence * sensitivity + (1 - disease prevalence) * specificity. Subgroup analyses were conducted using the whole non-treated cohort. To compare the AUROC between the subgroups defined by sex, age, study region, HBeAg, HBV genotype, and

HCV/HIV/HDV co-infection, the interaction test by Altman and Bland was conducted when comparing two groups,²¹ and one-way analysis of variance when comparing more than two groups.²² All the analyses were performed using STATA 13.0 (Stata Corporation, USA).

Results

Study Selection

A total of 10,863 titles and abstracts were screened, and 227 studies were assessed in full text for their eligibility (Figure 1). Of 74 studies that met our criteria, IPD were finally obtained for 60 studies (81%). The IPD were either reported in the original articles (4 studies) or shared by the corresponding authors (56 studies). After excluding 87 patients with HCC and 586 patients with incomplete information, the analysis finally included a total of 10,397 IPD: 5,591 patients without antiviral therapy (50 studies from 23 centers) and 4,806 patients under antivirals (39 studies from 19 centers). The vast majority of patients under treatment (94%, n=4,511) received nucleos(t)ide analogues (NA), and only few (6%, n=278) had interferon-based therapy (IFN). Characteristics of the included studies by study center are summarized in Table 1. The study was conducted in Asia (n=50), Europe (n=9), and Africa (n=1). All the studies used serum samples to measure HBcrAg with a chemiluminescent immunoassay (Lumipulse®, Fujirebio Inc., Tokyo, Japan). HBV DNA was quantified by RT-PCR in majority of samples (10,103; 98%), using the following assays: COBAS TaqMan (n=8,044) and Amplicor (n=797) (Roche Diagnostics); RealTime/AccuGene (n=400) (Abbott); and in-house methods (n=862). The rest (157 samples; 2%) was tested using transcription mediated amplification (TMA): TMA, Chugai Diagnostics (n=104); and DNA Probe FR-HBV, Fujirebio (n=53).

Characteristics of the included studies

Table 2 presents the patients' characteristics by the concurrent anti-HBV treatment. Median age (years) was 45 (IQR: 34-57) in non-treated and 56 (45-64) in treated group. HBeAg was positive in 37% of non-treated and 31% of treated group. Whilst proportion with undetectable HBV DNA was significantly higher in treated (64%) than in non-treated (12%, $p<0.001$), the proportion with undetectable HBcrAg was similar in treated (26%) and non-treated (32%, $p=0.4$). Of note, for those

with undetectable HBV DNA, only the minority had detectable HBcrAg in non-treated group (27%, 189/692), but the majority had detectable HBcrAg in treated group (69%, 2,114/3,080, $p=0.002$).

Risk-of-Bias Assessment

The risk-of-bias is summarized for all 60 included studies (Supplementary Figure 1) and for each study (Supplementary Figure 2). Only 16 studies enrolled a consecutive/random sample. Some studies restricted participants to be HBeAg-positive ($n=13$), HBeAg-negative ($n=7$), having high viral load ($n=9$), or low viral load ($n=5$), which raised concern about applicability of these studies. Except 13 studies, the objective of the original work was not to assess the correlation between HBcrAg and HBV DNA. No study, but one,¹⁴ mentioned whether those examined HBcrAg were blinded to the results of HBV DNA, and vice versa.

Correlation between serum HBcrAg levels and HBV DNA levels

Figure 2 presents the scatter plot of HBcrAg and HBV DNA with the LOWESS in patients without antiviral therapy. The correlation was observed irrespective of viral genotypes. Pearson's correlation coefficient was 0.84 for all untreated subjects, and 0.83, 0.84, 0.83, 0.85, and 0.82 for genotype A, B, C, D, and E, respectively. The scatter plot of HBcrAg and HBV DNA in non-treated patients by HBeAg positivity is presented in the Supplementary Figure 3. In contrast with those without antiviral treatment, the correlation was poor in patients under treatment ($r=0.54$) (Supplementary Figure 4), and therefore the subsequent analyses were not performed in this group.

Performance of HBcrAg to diagnose high viral load in non-treated patients

In patients without antiviral therapy, the pooled AUROC was: 0.88 (95% CI: 0.83-0.94) for the diagnosis of HBV DNA levels of $\geq 2,000$ IU/ml; 0.95 (0.93-0.97) for $\geq 20,000$ IU/ml; and 0.96 (0.94-0.98) for $\geq 200,000$ IU/ml (Figure 3). To obtain the optimal cut-offs, the non-treated cohort was randomly divided into two: derivation and validation set. These groups had similar characteristics (Supplementary Table 1). The optimal cut-offs (log U/ml) were 3.6, 4.5, and 5.3 to diagnose HBV DNA levels (IU/ml) of $\geq 2,000$, $\geq 20,000$, and $\geq 200,000$, respectively, using the derivation set. By

applying these to the validation set, the sensitivity, specificity, and the proportion correctly classified were: 85.2%, 84.7% and 85.0% for $\geq 2,000$ IU/ml, 90.4%, 91.9% and 91.1% for $\geq 20,000$ IU/ml, and 91.8%, 90.5% and 91.1% for $\geq 200,000$ IU/ml, respectively (Table 3).

Subgroup analysis in non-treated patients

The pooled AUROCs did not vary according to the sex, age groups (<30 or ≥ 30 years), study regions (Asia, Europe, or Africa), HBV genotypes (A/B/C/D/E), HCV, or HDV co-infection (Table 3). Across the different viral genotypes, the AUROCs were constantly ≥ 0.80 , ≥ 0.93 and ≥ 0.95 to diagnose viremia of $\geq 2,000$, $\geq 20,000$ and $\geq 200,000$ IU/ml, respectively. In 1,134 women of reproductive age (15-49 years), the AUROC was 0.98 (95% CI: 0.96-1.00) with a sensitivity of 94.1% and a specificity of 89.5% to diagnose HBV DNA thresholds requiring peripartum antiviral prophylaxis (i.e., viral load $\geq 200,000$ IU/ml). A *post-hoc* analysis was performed in the women of reproductive age for the performance of HBeAg; although mean viral load (\pm standard deviation) was much higher in HBeA-positive women (7.18 ± 1.81 log IU/ml) than in HBeAg-negative women (3.07 ± 1.90 log IU/ml), the AUROC of HBeAg was 0.76 (95% CI: 0.64-0.88) to discriminate between high and low viral loads at the cut-off level of $\geq 200,000$ IU/ml.

The performance of HBcrAg to diagnose viral load $\geq 2,000$ IU/ml differed according to the HBeAg sero-status (P for interaction for AUROC < 0.01); the sensitivity and specificity were 97.9% and 23.4% in HBeAg-positive and 66.0% and 87.2% in HBeAg-negative group, respectively. The low specificity in HBeAg-positive group and low sensitivity in HBeAg-negative group, however, had minimal impact on the overall misclassification in each sub-group. The high false positive rate (76.6%) in HBeAg-positive group was offset by the small prevalence (3.9%) of low viremia ($< 2,000$ IU/ml) in this group, resulting in 95.0% of HBeAg-positive patients being correctly classified by HBcrAg (Table 3). Similarly, low sensitivity (66.0%) in HBeAg-negative group was relevant in only the minority (37.0%) of those with high viremia ($\geq 2,000$ IU/ml), which led to 79.4% of HBeAg-negative patients being correctly classified.

Discussion

This systematic review successfully obtained the IPD from the majority of eligible studies (81%, 60/74). This allowed us to synthesize robust estimates using large, well-characterized datasets with varying virological and epidemiological background. Despite the heterogeneity among reference assays used to quantify HBV DNA across the studies, we found: (i) a close correlation between HBcrAg and HBV DNA and excellent performance of HBcrAg levels to indicate clinically important viral load irrespective of HBV genotypes in CHB patients without antiviral therapy; and (ii) lack of correlation in those treated with antivirals.

In high-income countries, HBcrAg is increasingly recognized as a surrogate marker for cccDNA amount and its transcriptional activity, and useful tool to monitor the treatment response.^{16,23,24} Although quantification of intrahepatic amount of cccDNA, a key genomic form responsible for the persistence of infection, should be highly informative to manage CHB patients, this requires liver biopsy and therefore cannot be routinely performed. Instead, serum HBV DNA has been clinically used as a routine biomarker for HBV replication. In patients under antiviral therapy, however, discrepancies become apparent between intrahepatic cccDNA and serum HBV DNA levels; while nucleos(t)ides analogues inhibit reverse transcription and almost invariably lead to undetectable serum HBV DNA, intrahepatic cccDNA often persists despite long-term treatment.²⁵ Next commonly used marker for HBV replication is quantification of serum HBsAg. However, its correlation with cccDNA is also limited, particularly in HBeAg-negative patients, because HBsAg is derived not only from intrahepatic cccDNA but also from HBV DNA sequences integrated into the host genome.²⁶ Contrary to these conventional biomarkers, a close correlation between serum HBcrAg and intrahepatic cccDNA has been observed in treatment-naïve patients,^{10,11,15,16,27-29} and also in those who underwent anti-HBV therapy in whom a magnitude of reduction in HBcrAg is well correlated with that of cccDNA.^{10,11,15,27} Not surprisingly, in this meta-analysis, poor correlation was confirmed between HBV DNA and HBcrAg in patients under treatment, and the majority (69%) of the treated patients with undetectable serum HBV DNA still carried detectable HBcrAg. These results are consistent with

the previous findings, and support the utility of serum HBcrAg as an endpoint for novel anti-HBV drugs aiming at a complete cure of HBV infection.^{16,24}

In addition to its great potential as a tool to monitor patients under treatment, serum HBcrAg may also be useful to indicate clinically important HBV DNA levels in treatment-naïve patients, as suggested by our meta-analysis. This may support its use as an alternative to NAT to select patients in need of antiviral therapy subsequent to a positive HBsAg screening result. A recent African study demonstrated a sensitivity of 96.6% and specificity of 85.8% for a simplified treatment algorithm using HBcrAg to indicate the treatment eligibility determined by the reference tests including HBV DNA quantification.¹⁴ Furthermore, some studies suggested that HBcrAg might be even more accurate than HBV DNA levels to predict liver disease progression in treatment-naïve patients. A long-term follow-up of a large Japanese cohort of CHB patients without anti-HBV treatment found that quantification of HBcrAg was superior to serum viral load to predict the development of HCC,³⁰ and cirrhosis.³¹ In a recent study in Taiwan also confirmed the independent association between serum HBcrAg levels and HCC development.³²

A recent advent of inexpensive automated point-of-care PCR assays, such as GeneXpert, may help to overcome the limited access to the conventional NAT assays in LMICs. To further decentralize clinical staging of CHB, there is a need to develop an assay fully adapted to resource-limited primary healthcare settings without air-conditioning or uninterrupted electricity supply.³³ Indeed, the development of an inexpensive rapid test based on lateral-flow technology to detect HBcrAg is currently ongoing, and its evaluation will be performed in LMICs. Lowering the detection limit for such a test may be less relevant; for example, a rapid test detecting high HBcrAg levels of ≥ 5.3 log U/ml (equivalent to viral load of $\geq 200,000$ IU/ml) should be extremely useful at antenatal care to select pregnant women for anti-HBV therapy to prevent mother-to-child transmission, because of its high clinical sensitivity (94.1%) and specificity (89.5%) to indicate HBV DNA levels at risk of immunoprophylaxis failure. In addition, analytical sensitivity of HBcrAg has been recently improved (detection limit of highly sensitive HBcrAg assay: 2.1 log U/mL, personal communication), which

may lead to future development of rapid test targeting lower thresholds equivalent to viral loads of $\geq 2,000$ or $\geq 20,000$ IU/ml.

As a limitation, most included studies are from high-income countries and mainly from Asia with an over-representation of HBV genotypes B and C. Studies are needed from other geographical regions, particularly those from resource-limited countries. Second, clinical sensitivity of HBcrAg for viral load $\geq 2,000$ IU/ml was moderate (66.0%) in HBeAg-negative patients. This may have an impact in countries where the prevalence of HBeAg is low (e.g., in Africa). Nevertheless, by applying the data from a large population-based study in West Africa (96.7% of adults with CHB infection being negative for HBeAg, and 8.5% of those negative for HBeAg had viral load $\geq 2,000$ IU/ml),³⁴ the use of HBcrAg would still correctly classify 85.4% of HBeAg-negative African people for diagnosing $\geq 2,000$ IU/ml. New version of the HBcrAg assay with an improved analytical sensitivity (2.1 log U/mL) will be available in near future, and this should further increase the diagnostic sensitivity. Moreover, there are recent publications supporting the usefulness of HBcrAg in HBeAg-negative patients.^{35,36} Third, we could not assess the performance of HBcrAg to indicate treatment eligibility *per se*. The treatment eligibility criteria, apart from those for pregnant women for the prevention of mother-to-child transmission, are composed of a combination of multiple factors, and HBV viral load merely represents one of these. In this study, we did not seek individual participant data for liver inflammation or fibrosis. Fourth, the included studies suffered from the risk-of-bias. None, but one, reported that the index test was performed by staff blinded to the result of the reference test, and vice versa, because most of the original studies were not designed to evaluate the performance of HBcrAg to diagnose HBV viral load.

LMICs account for the highest HBV burden, yet, face enormous challenges in scaling up treatment services with the limited access to NAT assays. HBcrAg, an attractive alternative to HBV DNA RT-PCR, has potential to contribute to the global elimination goals. Further studies, particularly those assessing the feasibility and cost-effectiveness of HBcrAg assays in LMICs, are highly deserved.

Acknowledgements

We thank co-authors and study participants of all the original studies that were included in this meta-analysis.

Funding

None

Journal Pre-proof

References

1. WHO. Global Hepatitis Report, 2017. Geneva, Switzerland, 2017.
2. WHO. Guidelines on Hepatitis B and C Testing. Geneva, Switzerland, 2017.
3. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017;67:370-398.
4. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* 2018;67:1560-1599.
5. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol Int* 2016;10:1-98.
6. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *Lancet Gastroenterol Hepatol* 2018;3:383-403.
7. Freiman JM, Tran TM, Schumacher SG, et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: A systematic review and meta-analysis. *Ann Intern Med* 2016;165:345-355.
8. Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. *J Clin Microbiol* 2002;40:439-445.
9. Ning X, Basagoudanavar SH, Liu K, et al. Capsid Phosphorylation State and Hepadnavirus Virion Secretion. *J Virol* 2017;91.
10. Wong DKH, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. *J Clin Microbiol* 2007;45:3942-3947.
11. Suzuki F, Miyakoshi H, Kobayashi M, et al. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. *J Med Virol* 2009;81:27-33.
12. Maasoumy B, Wiegand SB, Jaroszewicz J, et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. *Clin Microbiol Infect* 2015;21:606.e1-

- 606.e10.
13. Riveiro-Barciela M, Bes M, Rodríguez-Frías F, et al. Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype. *Clin Microbiol Infect* 2017;23:860-867.
 14. Shimakawa Y, Ndow G, Njie R, et al. Hepatitis B core-related antigen: an alternative to hepatitis B virus DNA to assess treatment eligibility in Africa. *Clin Infect Dis* 2019.
 15. Wong DKH, Seto WK, Cheung KS, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. *Liver Int* 2017;37:995-1001.
 16. Testoni B, Lebossé F, Scholtes C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. *J Hepatol* 2019;70:615-625.
 17. Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: The PRISMA-IPD statement. *JAMA* 2015;313:1657-1665.
 18. Whiting PF, Rutjes AWS, Westwood ME, et al. Quadas-2: A revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;155:529-536.
 19. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: Rationale, conduct, and reporting. *BMJ* 2010;340:521-525.
 20. Alonzo TA, Pepe MS. Distribution-free ROC analysis using binary regression techniques. *Biostatistics* 2002;3:421-432.
 21. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003;326:219.
 22. Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: A systematic review and meta-analysis of individual participant data. *Clin Gastroenterol Hepatol* 2015;13:440-451.
 23. Tanaka E, Matsumoto A. Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B. *Hepatol Res* 2014;44:1-8.
 24. Mak LY, Wong DKH, Cheung KS, et al. Review article: hepatitis B core-related antigen

- (HBcrAg): an emerging marker for chronic hepatitis B virus infection. *Aliment Pharmacol Ther* 2018;47:43-54.
25. Lai C-L, Wong D, Ip P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. *J Hepatol* 2017;66:275-281.
 26. Cornberg M, Wong VWS, Locarnini S, et al. The role of quantitative hepatitis B surface antigen revisited. *J Hepatol* 2017;66:398-411.
 27. Chen EQ, Feng S, Wang ML, et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. *Sci Rep* 2017;7:1-8.
 28. Chuaypen N, Posuwan N, Chittmittraprap S, et al. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy. *Clin Microbiol Infect* 2018;24:306.e7-306.e13.
 29. Chen EQ, Wang ML, Tao YC, et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA. *J Viral Hepat* 2019;26:586-595.
 30. Tada T, Kumada T, Toyoda H, et al. HBcrAg is a predictor of hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics. *J Hepatol* 2016;65:48-56.
 31. Tada T, Kumada T, Toyoda H, et al. Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. *J Gastroenterol Hepatol* 2018;33:918-925.
 32. Tseng T-C, Liu C-J, Hsu C-Y, et al. High Level of Hepatitis B Core-related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. *Gastroenterology* 2019.
 33. Ndlovu Z, Fajardo E, Mbofana E, et al. Multidisease testing for HIV and TB using the GeneXpert platform: A feasibility study in rural Zimbabwe. *PLoS One* 2018;13:1-13.
 34. Lemoine M, Shimakawa Y, Njie R, et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. *Lancet Glob Heal* 2016;4:e559-e567.
 35. Zhang ZQ, Wang YB, Lu W, et al. Performance of hepatitis B core-related antigen versus

- hepatitis B surface antigen and hepatitis B Virus DNA in predicting HBeAg-positive and HBeAg-negative chronic hepatitis. *Ann Lab Med* 2018;39:67-75.
36. Loggi E, Vukotic R, Conti F, et al. Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B. *J Viral Hepat* 2019;26:568-575.

Journal Pre-proof

Figure Legends

Figure 1. Flow diagram of study selection

Figure 2. Correlation between HBcrAg & HBV DNA levels with locally weighted scatter plot smoothing (LOWESS) in patients without treatment, by viral genotypes

Figure 3. Receiver operating characteristic curves for HBcrAg to diagnose clinically important HBV DNA levels (dash: $\geq 2,000$ IU/ml; short dash: $\geq 20,000$; solid: $\geq 200,000$)